Board of Directors

Mr. Moore has served as a member of our board of directors and our chair since February 2018. Mr. Moore has served as Chairman of the Board for medical device company LivaNova, PLC (NASDAQ: LIVN) since September 2015. He has served as a member of the board of directors for GI Dynamics, Inc.(ASX: GID), a medical device company since September 2014. Since January 2012, Mr. Moore has served as a member of the board of directors of medical device company, BrainScope. He served as a member of the board of directors of TriVascular (NASDAQ: TRIV), a medical device company, from September 2010 to January 2016. From May 2007 to October 2015, Mr. Moore served as Chief Executive Officer as well as a member of the board of directors of Cyberonics, Inc. (NASDAQ: CYBX), a medical device company. He served as a member of the board of directors for Topera, Inc., a medical device company, from October 2013 to January 2015. From 1989 to 2007, Mr. Moore held various positions in sales, marketing and senior management for Boston Scientific Corporation (NYSE: BSX). He was a member of the board of directors of the Medical Device Innovation Consortium (MDIC) from 2012 to 2014. From 2009 to 2016, Mr. Moore was a member of the board of directors of the Medical Device Manufacturers Association (MDMA), serving as Chair from 2012 to 2014. He was a member of the board of directors of the Epilepsy Foundations of Texas and Houston from 2008-2014, and a member of the board of directors of Smiling Kids, Inc. from 2000 to 2008. Mr. Moore holds a B.A. from Harvard University, and an M.B.A. from Boston University. We believe Mr. Moore is qualified to serve on our board of directors based on his diverse domestic and global business experience in the medical device industry.

Mr. Grossman has served as a member of our board of directors since July 2018. Mr. Grossman has over 30 years of leadership experience in the medical technology industry. As of April, 2019, he serves as a Vice Chairman of Alcon, Inc. (NYSE: ALC). Mr. Grossman also serves as President and Chief Executive Officer and a member of the board of directors for Nevro Corp. (NYSE: NVRO), a medical device company since March 2019. Since 2015, he has served as a member of the board of directors of TherOx, Inc., a medical device company. Since 2014, Mr. Grossman has served as a member of the board of directors of Outset Medical, Inc., a medical device company. He served as a member of the board of directors of Vyaire Medical, Inc. from October 2016 until March 2019. Mr. Grossman served as a member of the board of directors of Zeltiq Asthetics, Inc. (NASDAQ: ZLTQ), a medical technology company, from October 2013 to May 2017. He served as its Lead Independent Director from February 2016 to April 2017. Mr. Grossman served as a member of the board of directors of Thoratec Corporation (NASDAQ: THOR), a medical device company, from January 1996 to October 2015. From 2014 to 2016, he also served as President and Chief Executive Officer of Thoratec. Mr. Grossman served as President and CEO as well as a member of the board of directors of Conceptus, Inc. (NASDAQ: CPTS), a medical device company, from September 2011 to June 2013. From 2010 to 2012, he served as a member of the board of directors of Conventus Orthopaedics, Inc., a medical device company, as well as a member of the board of directors of Tandem Diabetes Care, Inc. (NASDAQ: TNDM), also a medical device company. Mr. Grossman served as a member of the board of directors of PatientSafe Solutions, Inc. from 2009 to 2012. From 2008 to 2012, he served as a member of the board of directors of NovaSom, Inc., a medical technology company, as well as a member of the board of directors of Vibrynt, Inc., a medical device company. Mr. Grossman served as a member of the board of directors of Intuitive Surgical, Inc. (NASDAQ: ISRG), a medical device company, from April 2003 to April 2010. He served as a member of the board of directors of medical device company, Kyphon, Inc. (NASDAQ: KYPH) from 2006 to November 2007. From 2003 to 2007, Mr. Grossman served on the board of directors of Acorn Cardiovascular, Inc., a medical device company. He served as a Managing Director for TPG Biotech, L.P., a private equity firm from September 2007 to December 2011. Mr. Grossman served as a board member of the Medical Device Manufacturers Association (MDMA) from 2011 to 2014, and as a member of the board of directors of The Tom Burnett Family Foundation from 2001 to 2005. He holds a B.S. from Ohio State University and an M.B.A. from Pepperdine University. We believe Mr. Grossman is qualified to serve on our board of directors because of his over 30 years of experience in leading innovative medical technology companies, delivering value to patients and customers as well as growth for stockholders.

Brian K. Roberts has served as a member of our board of directors since December 2015. Since January 2018, Mr. Roberts has served as Chief Financial Officer of Tarveda Therapeutics, Inc., a biopharmaceutical company. Since July 2016, he has served as a member of the board of directors for Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company. Mr. Roberts served as Chief Operating and Financial Officer at Avedro, Inc., a pharmaceutical and medical device company, from January 2015 to October 2016. He served as Chief Financial Officer at Insulet Corporation (NASDAQ: PODD), also a medical device company, from March 2009 to November 2014. Mr. Roberts served as Chief Financial Officer at Jingle Networks, Inc., an advertising and technology solutions company, from September 2007 to December 2008. From June 2001 to July 2007, he held various leadership roles, including serving as Chief Financial Officer of Digitas, Inc. (NASDAQ: DTAS), (a/k/a DigitasLBi, Inc.), a marketing and technology agency. Mr. Roberts served as Vice President of Finance at Idiom Technologies, Inc., a provider of globalization management, from January 2000 to June 2001. From 1997 to 1999, he served as U.S. Controller of The Monitor Group, a consulting firm. Mr. Roberts served as an Auditor with Ernst & Young LLP from 1993 to 1997. He holds a B.S. from Boston College. We believe Mr. Roberts is qualified to serve on the Board because of his over 20 years of financial, operational and strategic experience in private and public companies.

Scott Drake is a proven leader in the medical device space. He is currently the President and CEO of ViewRay, an MRI-guided radiation therapy company with leading technology. Previously, Scott was President and CEO of Spectranetics, a publicly traded medical device company. During his six-year tenure, shareholder value increased from approximately $170 million to $2.2 billion when acquired by Royal Philips. Prior to Spectranetics, he spent 17 years in leadership positions within numerous health care business units at Covidien, including President of Covidien’s $1.5 billion Respiratory and Monitoring Solutions Global Business. Drake serves as Chairman of the Board for AtriCure (NASDAQ: ATRC) and as the Chairperson of the AdvaMed Radiation Therapy Sector. He previously served on the Board of Directors for The Zayo Group Holdings, Inc, which was acquired by Digital Colony and EQT for $14.3 billion. In 2014 he was named an Ernst and Young Entrepreneur of the Year.

Mr. Huennekens has served as a member of our board of directors since February 2018. Mr. Huennekens has served as a member of the board of directors for NuVasive, Inc. (NASDAQ: NUVA), a medical device company, since September 2018. He has served on as Executive Chairman of the Board of Directors of Acutus Medical, a medical device company, since July 2019. Mr. Huennekens served as Chairman of the Board, President and Chief Executive Officer of Verb Surgical, Inc., a medical device company, from August 2015 to January 2019. He served as a member of the board of directors of REVA Medical, Inc. (ASX: RVA), a medical device company from April 2015 to May 2018. From April 2013 to November 2016, he served as a member of the board of directors as well as Chairman of the Board at EndoChoice, Inc. and EndoChoice Holdings, Inc. (NYSE: GI), a medical device company. Mr. Huennekens served as President and Chief Executive Officer, and as a member of the board of directors of Volcano Corporation (NASDAQ: VOLC), a medical device company, from March 2002 to February 2015. From March 1997 to March 2002, he served in leadership roles, including President and Chief Executive Officer for Digirad Corporation (NASDAQ: DRAD), a diagnostic imaging solutions provider. Mr. Huennekens served in various leadership roles in divisions of Baxter International, Inc. (NYSE: BAX) from July 1993 to March 1997. From August 1991 to June 1993, he worked for Birtcher Medical Systems, Inc., and from September 1986 to August 1989, Mr. Huennekens served as an Audit Senior for Deloitte & Touche. Since 2009, Mr. Huennekens has served as a member of the board of directors, and from 2014 to 2016 was Chairman of the board of directors for the Medical Device Manufacturer’s Association (MDMA). He holds a B.S. from the University of Southern California and an M.B.A. from the Harvard Business School. We believe Mr. Huennekens is qualified to serve on our board of based on his over 25 years of extensive experience in the medical device industry, developing advanced and innovative technological initiatives.

Dr. Wilensky has served as a member of our board of directors since July 2019. She has served as a Senior Fellow at Project HOPE, an international non-profit health foundation, since January 1993. She has served as a member of the board of directors of UnitedHealth Group, Inc. (NYSE: UNH), a health and well-being services company, since January 1993. Dr. Wilensky has served as a member of the board of directors of Quest Diagnostics, Inc. (NYSE: DGX), a diagnostic testing and information company, since January 1997. She served in the Department of Defense as President and Chair, Health Care Advisory Subcommittee from September 2008 through August 2009, and from December 2006 to March 2008 as Co-Chair, Task Force on the Future of Military Health. Dr. Wilensky served as Co-Chair and Presidential Appointee of the Task Force to Improve Healthcare Delivery for the Nation’s Veterans from June 2001 to May 2003. From October 1997 to October 2001, she served as Chair of the Medicare Payment Advisory Committee. She served as Chair of the Physician Payment Review Commission from May 1995 to September 1997. From March 1992 to January 1993, Dr. Wilensky served as Deputy Assistant to the President for Policy Development. She served as Administrator of the Health Care Financing Administration (now known as the Centers for Medicare and Medicaid Services) directing the Medicaid and Medicare programs for the United States from January 1990 to March 1992. Dr. Wilensky serves on the Board of Regents of the Uniformed Services University of the Health Sciences (USUHS) and the Geisinger Health System Foundation and is an elected member of the National Academy of Medicine. She holds a B.A., M.A., and Ph.D. from the University of Michigan.  We believe Dr. Wilensky is qualified to serve on our board based on her extensive experience as an economist, as well as her advisory and policy-making work in the medical technology and healthcare fields.

Caley Castelein, M.D. has served as a member of our board of directors since January 2008. Since February 2017, Dr. Castelein has served as a member of the board of directors of Aerpio Therapeutics, Inc. (NASDAQ: ARPO), a biopharmaceutical company. He has served as a member of the board of directors for AliveCor, Inc., a medical device company and NewBridge Pharmaceuticals FZ, LLC, a specialty therapeutics company, since March 2015. Since October 2010, Dr. Castelein has served as a member of the board of directors of Boreal Genomics, Inc. Since March 2008, he has served as a Managing Director of Kearny Venture Partners, L.P. Additionally he founded KVP Capital, L.P. in 2013 and manages the fund which invests in small and mid-cap healthcare companies. Dr. Castelein served as a member of the board of directors for Waterstone Pharmaceuticals, Inc., a pharmaceutical company from March 2015 to March 2018. From March 2015 to November 2017, he served as a member of the board of directors of Wellpartner, Inc., a pharmaceutical distribution solutions company. From March 2015 to July 2015, Dr. Castelein served as a member of the board of directors of Neos Therapeutics, Inc. (NASDAQ: NEOS), a pharmaceutical company. He holds an A.B. from Harvard College and an M.D. from the University of California, San Francisco. We believe Dr. Castelein is qualified to serve on our board of directors based on his extensive investment experience in the healthcare industry.

Ms. Johnson has served as a member of the Board of Directors since April of 2020. She is currently President and General Manager of Affinity Capital Management, a venture capital firm that invests primarily in seed and early-stage health care companies in the United States, a position she has held since 2000. Ms. Johnson also currently serves on the Board of Directors for AtriCure (Nasdaq: ATRC) and ClearPoint Neuro, Inc. (Nasdaq: CLPT), both medical technology companies.

Ms. Johnson held several leadership roles at Medtronic (NYSE: MDT) over the course of 17 years, serving most recently as Senior Vice President and Chief Administrative Officer. Her experience at Medtronic included President and General Manager of its vascular business and President and General Manager of its tachyarrhythmia management business, among other roles. 

Ms. Johnson previously served on the Board of Directors of The Spectranetics Corporation, a medical device company which was acquired by Royal Philips, ADC Telecommunications, which was acquired by Tyco Electronics, and Pentair, an industrial manufacturing company. She also served as a member of the board of directors of Piper Sandler (formerly Piper Jaffray), an investment banking firm, from 2003 to 2019. She was lead director for Piper Sandler from 2012 to 2018. Ms. Johnson is also currently Chair of the Investment Advisory Board of the University of Minnesota Foundation and serves on the boards of several private entities. She received her B.A. from St. Olaf College.
 

Kevin Xie, Ph.D. has served as a member of our board of directors since October 2019. He has served as President of Healthcare Holdings for Fosun Group, a Chinese international conglomerate and investment company, and Chief Representative of Fosun, NY since March 2015. From February 2012 to March 2015, Dr. Xie served as Managing Partner for Kinglington Capital, an investment company. He co-founded and served as Portfolio Manager for Locust Walk Capital from April 2010 to February 2012. From January 2009 to January 2010, Dr. Xie served as Healthcare Sector Head for Scopia Capital, a global hedge fund. From 2005-2008, he served as Principal and subsequently Managing Director for Great Point Partners, a healthcare hedge fund. Dr. Xie served as an Equity Analyst for Delaware Investments, an asset management firm, from June 2002 to July 2005. From 1999-2001, he served as Project Leader and Senior Scientist for Boehringer Ingelheim Pharmaceuticals, Inc. Dr. Xie holds a B.S. from Tianjin University in China, a Ph.D. from The City University in New York, and an M.B.A. from The Wharton School, University of Pennsylvania. We believe Dr. Xie is qualified to serve on our board based on his extensive expertise in the healthcare industry.